chronic migraine
Neurology · 2011–2024
15decisions
7medicines
11carried consumer input
716individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| erenumab Prophylaxis of chronic migraine in adults who have experienced an inadequate response, intolerance or a contraindication to at least 3 prophylactic migraine… | Nov 2024 | Recommended | 51 individuals |
| atogepant Prophylaxis of chronic migraine and high-frequency episodic migraine in adults who have experienced an inadequate response, intolerance or a contraindication… | Jul 2023 | Not recommended | input received Headache Australia · Migraine Australia |
| eptinezumab Preventive treatment of chronic migraine in patients with inadequate response, intolerance or contraindication to at least three prior prophylactic migraine… | Jul 2022 | Recommended with restriction | 85 individuals Headache Australia · Migraine Australia · ANZ Headache Society |
| fremanezumab Chronic migraine in patients with inadequate response, intolerance, or contraindication to at least three prophylactic migraine medications. | Mar 2022 | Recommended with restriction | 18 individuals |
| fremanezumab Continuing treatment of chronic migraine in patients who have previously received PBS-subsidised fremanezumab monthly and achieved ≥50% reduction in migraine… | Mar 2022 | Recommended | 1 individuals |
| fremanezumab Treatment of chronic migraine in patients who have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic… | Mar 2020 | Recommended with restriction | no section in document |
| galcanezumab Prophylaxis of migraine in adults; specifically for the treatment of chronic migraine in patients who have experienced an inadequate response, intolerance or a… | Nov 2020 | Recommended with restriction | 186 individuals |
| galcanezumab Treatment of chronic migraine in adult patients who have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic… | Jul 2019 | Recommended with restriction | 56 individuals |
| erenumab Prophylaxis of migraine in adults; specifically chronic migraine in patients who have experienced inadequate response, intolerance, or contraindication to at… | Mar 2019 | Not recommended | 258 individuals |
| fremanezumab Treatment of chronic migraine in patients who have experienced an inadequate response, intolerance or contraindication to at least three prophylactic migraine… | Nov 2019 | Deferred | 57 individuals |
| erenumab Chronic migraine in adult patients who have experienced an inadequate response, intolerance or contraindication to at least three prophylactic migraine… | Jul 2018 | Not recommended | input received |
| botulinum toxin type A Prophylaxis of headaches in adults with chronic migraine who have experienced an average of 15 or more headache days per month with at least 8 days of migraine… | Mar 2018 | Not recommended | 4 individuals |
| botulinum toxin type A Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine) who have… | Jul 2013 | Recommended with restriction | unclear |
| Botulinum Toxin Type A Purified Neurotoxin Complex Prophylaxis of headaches in adult patients with chronic migraine who meet certain criteria, specifically those who have experienced an average of 15 or more… | Jul 2012 | Recommended | unclear |
| botulinum toxin type A prophylaxis of headaches in an adult patient with chronic migraine who meets certain criteria, including having experienced an average of 15 or more headache… | Nov 2011 | Not recommended | unclear |
Who spoke
Headache Australia · Migraine Australia · ANZ Headache Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 11 of 12 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.